{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:13:19Z","timestamp":1776726799702,"version":"3.51.2"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>One of the major consequences of the lack of a functional VHL protein in von Hippel-Lindau disease, a rare cancer, is the constitutive activation of the HIF pathway. This activation ends up in the generation of Central Nervous System (CNS) Hemangioblastomas among other tumours along the lifespan of the patient. Nowadays, only surgery has been proven efficient as therapy since the systemic attempts have failed. Propranolol, a non-specific \u03b21-and \u03b22-adrenergic receptor antagonist, was recently designated as the first therapeutic (orphan) drug for VHL disease. Nevertheless, its \u03b21 affinity provokes the decrease in blood pressure, being not recommended for low or regular blood pressure VHL patients. In order to overcome the \u03b21-drawback, the properties of a high specific \u03b22-adrenergic receptor blocker named ICI-118,551 have been studied. ICI-118,551 was able to decrease Hemangioblastomas cell viability in a specific manner, by triggering apoptosis. Moreover, ICI-118,551 also impaired the nuclear internalization of HIF-1\u03b1 in Hemangioblastomas and hypoxic primary endothelial cells, reducing significantly the activation of HIF-target genes and halting the tumour-related angiogenic processes. In this work, we demonstrate the therapeutical properties of ICI-118,551 in VHL-derived CNS-Hemangioblastoma primary cultures, becoming a promising drug for VHL disease and other HIF-related diseases.<\/jats:p>","DOI":"10.1038\/s41598-019-46448-6","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T13:50:39Z","timestamp":1562853039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The \u03b22-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease"],"prefix":"10.1038","volume":"9","author":[{"given":"A. M.","family":"Cuesta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Albi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gallardo-Vara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Recio-Poveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"de Rojas-P","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Villar G\u00f3mez","family":"de Las Heras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. T.","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"Botella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"key":"46448_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ejhg.2010.175","volume":"19","author":"ER Maher","year":"2011","unstructured":"Maher, E. R., Neumann, H. P. & Richard, S. Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 19, 617\u2013623 (2011).","journal-title":"Eur J Hum Genet"},{"key":"46448_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.semcancer.2012.05.005","volume":"23","author":"S Richard","year":"2013","unstructured":"Richard, S., Gardie, B., Couv\u00e9, S. & Gad, S. Von Hippel-Lindau: how a rare disease illuminates cancer biology. Semin Cancer Biol. 23, 26\u201337 (2013).","journal-title":"Semin Cancer Biol"},{"key":"46448_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/jnnp.70.5.644","volume":"70","author":"S Gl\u00e4sker","year":"2001","unstructured":"Gl\u00e4sker, S. et al. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry. 70, 644\u2013648 (2001).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"46448_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"L Gossage","year":"2015","unstructured":"Gossage, L., Eisen, T. & Maher, E. R. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 15, 55\u201364 (2015).","journal-title":"Nat Rev Cancer"},{"key":"46448_CR5","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.febslet.2012.04.032","volume":"586","author":"HL Bader","year":"2012","unstructured":"Bader, H. L., Hsu, T. & Systemic, V. H. L. gene functions and the VHL disease. FEBS Lett. 586, 1562\u20131569 (2012).","journal-title":"FEBS Lett"},{"key":"46448_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3109\/08820538.2013.825281","volume":"28","author":"NM Haddad","year":"2013","unstructured":"Haddad, N. M., Cavallerano, J. D. & Silva, P. S. Von hippel-lindau disease: a genetic and clinical review. Semin Ophthalmol. 28, 377\u2013378 (2013).","journal-title":"Semin Ophthalmol"},{"key":"46448_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jocn.2013.10.023","volume":"21","author":"CD Kassardjian","year":"2014","unstructured":"Kassardjian, C. D., Macdonald, R. L. & Munoz, D. G. Hemangioblastomas in the elderly: epidemiology and clinical characteristics. J Clin Neurosci. 21, 1205\u20131208 (2014).","journal-title":"J Clin Neurosci"},{"key":"46448_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc885","volume":"2","author":"WG Kaelin","year":"2002","unstructured":"Kaelin, W. G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2, 673\u2013682 (2002).","journal-title":"Nat Rev Cancer"},{"key":"46448_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc2502","volume":"8","author":"WG Kaelin","year":"2008","unstructured":"Kaelin, W. G. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 8, 865\u2013873 (2008).","journal-title":"Nat Rev Cancer"},{"key":"46448_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrneph.2013.144","volume":"9","author":"B Bausch","year":"2013","unstructured":"Bausch, B. et al. Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol. 9, 529\u2013538 (2013).","journal-title":"Nat Rev Nephrol"},{"key":"46448_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00401-013-1091-z","volume":"125","author":"AO Vortmeyer","year":"2013","unstructured":"Vortmeyer, A. O., Falke, E. A., Gl\u00e4ske, S., Li, J. & Oldfield, E. H. Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms. Acta Neuropathol 125, 333\u2013350 (2013).","journal-title":"Acta Neuropathol"},{"key":"46448_CR12","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1227\/01.NEU.0000093497.81390.29","volume":"53","author":"V Van Velthoven","year":"2003","unstructured":"Van Velthoven, V., Reinacher, P. C., Klisch, J., Neumann, H. P. & Gl\u00e4sker, S. Treatment of intramedullary hemangioblastomas, with special attention to von Hippel-Lindau disease. Neurosurgery. 53, 1306\u20131313 (2003).","journal-title":"Neurosurgery."},{"key":"46448_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.critrevonc.2012.10.001","volume":"86","author":"JF Capitanio","year":"2013","unstructured":"Capitanio, J. F., Mazza, E., Motta, M., Mortini, P. & Reni, M. Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system. Crit Rev Oncol Hematol. 86, 69\u201384 (2013).","journal-title":"Crit Rev Oncol Hematol"},{"key":"46448_CR14","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S1470-2045(18)30487-X","volume":"19","author":"E Jonasch","year":"2018","unstructured":"Jonasch, E. et al. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 19, 1351\u20131359 (2018).","journal-title":"Lancet Oncol."},{"key":"46448_CR15","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C Leaute-Labreze","year":"2008","unstructured":"Leaute-Labreze, C. et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 358, 2649\u20132651 (2008).","journal-title":"N Engl J Med"},{"key":"46448_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2133.2010.09848.x","volume":"163","author":"CH Storch","year":"2010","unstructured":"Storch, C. H. & Hoeger, P. H. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 163, 269\u2013274 (2010).","journal-title":"Br J Dermatol"},{"key":"46448_CR17","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.ad.2011.05.003","volume":"102","author":"I Sanchez-Carpintero","year":"2011","unstructured":"Sanchez-Carpintero, I., Ruiz-Rodriguez, R. & Lopez-Gutierrez, J. C. Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations. Actas Dermosifiliogr. 102, 766\u2013779 (2011).","journal-title":"Actas Dermosifiliogr"},{"key":"46448_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze, C. et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 372, 735\u2013746 (2015).","journal-title":"N Engl J Med"},{"key":"46448_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0664-7","volume":"12","author":"V Albi\u00f1ana","year":"2017","unstructured":"Albi\u00f1ana, V. et al. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. Orphanet J Rare Dis 12, 122 (2017).","journal-title":"Orphanet J Rare Dis"},{"key":"46448_CR20","doi-asserted-by":"publisher","first-page":"e000203","DOI":"10.1136\/bmjophth-2018-000203","volume":"4","author":"B Gonz\u00e1lez-Rodr\u00edguez","year":"2019","unstructured":"Gonz\u00e1lez-Rodr\u00edguez, B. et al. Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial. BMJ Open. Ophthalmology 4, e000203, https:\/\/doi.org\/10.1136\/bmjophth-2018-000203 (2019).","journal-title":"BMJ Open. Ophthalmology"},{"key":"46448_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0343-5","volume":"10","author":"V Albi\u00f1ana","year":"2015","unstructured":"Albi\u00f1ana, V. et al. Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients. Orphanet J Rare Dis. 10, 118 (2015).","journal-title":"Orphanet J Rare Dis"},{"key":"46448_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5966\/sctm.2015-0076","volume":"5","author":"NC Munabi","year":"2016","unstructured":"Munabi, N. C. et al. Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation. Stem Cells Transl Med. 5, 45\u201355 (2016).","journal-title":"Stem Cells Transl Med"},{"key":"46448_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/toxsci\/kfm060","volume":"97","author":"HP Wong","year":"2007","unstructured":"Wong, H. P. et al. Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol Sci. 97, 279\u2013287 (2007).","journal-title":"Toxicol Sci."},{"key":"46448_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1471-4159.2011.07530.x","volume":"119","author":"D Martini","year":"2011","unstructured":"Martini, D. et al. Antiangiogenic effects of \u03b22 -adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem. 119, 1317\u201329 (2011).","journal-title":"J Neurochem"},{"key":"46448_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00441-014-1976-8","volume":"358","author":"F Sharifpanah","year":"2014","unstructured":"Sharifpanah, F., Saliu, F., Bekhite, M. M., Wartenberg, M. & Sauer, H. \u03b2-Adrenergic receptor antagonists inhibit vasculogenesis of embryonic stem cells by downregulation of nitric oxide generation and interference with VEGF signalling. Cell Tissue Res. 358, 443\u2013452 (2014).","journal-title":"Cell Tissue Res"},{"key":"46448_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1023\/B:CACO.0000036152.58271.5e","volume":"15","author":"L Perron","year":"2004","unstructured":"Perron, L., Bairati, I., Harel, F. & Meyer, F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control. 15, 535\u2013541 (2004).","journal-title":"Cancer Causes Control"},{"key":"46448_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.220707","volume":"204","author":"JA Nathanson","year":"1979","unstructured":"Nathanson, J. A. Beta-adrenergic-sensitive adenylate cyclase in secretory cells of choroid plexus. Science. 204, 843\u2013844 (1979).","journal-title":"Science."},{"key":"46448_CR28","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/0024-3205(80)90580-9","volume":"26","author":"JA Nathanson","year":"1980","unstructured":"Nathanson, J. A. Cerebral microvessels contain a beta 2-adrenergic receptor. Life Sci. 26, 1793\u20131799 (1980).","journal-title":"Life Sci."},{"key":"46448_CR29","first-page":"21","volume":"16","author":"KP Minneman","year":"1979","unstructured":"Minneman, K. P., Hegstrand, L. R. & Molinoff, P. B. The pharmacological specificity of beta-1 and beta-2 adrenergic receptors in rat heart and lung in vitro. Mol Pharmacol. 16, 21\u201333 (1979).","journal-title":"Mol Pharmacol."},{"key":"46448_CR30","first-page":"502","volume":"211","author":"KP Minneman","year":"1979","unstructured":"Minneman, K. P., Hedberg, A. & Molinoff, P. B. Comparison of beta adrenergic receptor subtypes in mammalian tissues. J Pharmacol Exp Ther. 211, 502\u2013508 (1979).","journal-title":"J Pharmacol Exp Ther"},{"key":"46448_CR31","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/0024-3205(80)90008-9","volume":"27","author":"SR O'Donnell","year":"1980","unstructured":"O\u2019Donnell, S. R. & Wanstall, J. C. Evidence that ICI 118, 551 is a potent, highly Beta 2-selective adrenoceptor antagonist and can be used to characterize Beta-adrenoceptor populations in tissues. Life Sci. 27, 671\u2013677 (1980).","journal-title":"Life Sci."},{"key":"46448_CR32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/00005344-198305000-00013","volume":"5","author":"AJ Bilski","year":"1983","unstructured":"Bilski, A. J., Halliday, S. E., Fitzgerald, J. D. & Wale, J. L. The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551). J Cardiovasc Pharmacol. 5, 430\u2013437 (1983).","journal-title":"J Cardiovasc Pharmacol"},{"key":"46448_CR33","unstructured":"Ruffolo, R. R. Jr. ed. Adrenoceptors: Structure, Function and Pharmacology. (Harwood Academic Publisher, Luxembourg, 1995)."},{"issue":"5","key":"46448_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/bja\/ael238","volume":"97","author":"GM Hare","year":"2006","unstructured":"Hare, G. M. et al. Beta2 adrenergic antagonist inhibits cerebral cortical oxygen delivery after severe haemodilution in rats. Br J Anaesth. 97(5), 617\u201323 (2006).","journal-title":"Br J Anaesth"},{"issue":"2","key":"46448_CR35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S1566-0702(02)00004-8","volume":"96","author":"S Uchida","year":"2002","unstructured":"Uchida, S., Kawashima, K. & Lee, T. J. Nicotine-induced NO-mediated increase in cortical cerebral blood flow is blocked by beta2-adrenoceptor antagonists in the anesthetized rats. Auton Neurosci. 96(2), 126\u201330 (2002).","journal-title":"Auton Neurosci."},{"issue":"204(1\u20132)","key":"46448_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0378-5173(00)00480-4","volume":"25","author":"RM Moresco","year":"2000","unstructured":"Moresco, R. M. et al. Synthesis and in vivo evaluation of [11C]ICI 118551 as a putative subtype selective beta2-adrenergic radioligand. Int J Pharm 25(204(1\u20132)), 101\u2013109 (2000).","journal-title":"Int J Pharm"},{"issue":"6","key":"46448_CR37","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/bcpt.12949","volume":"122","author":"MH Ozkan","year":"2018","unstructured":"Ozkan, M. H. & Uma, S. \u03b2-adrenergic Receptor Blocker ICI 118,551 Selectively Increases Intermediate-Conductance Calcium-Activated Potassium Channel (IK(Ca))-Mediated Relaxations in Rat Main Mesenteric Artery. Basic Clin Pharmacol Toxicol. 122(6), 570\u2013576 (2018).","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"46448_CR38","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3892\/etm.2016.3450","volume":"12","author":"H Gong","year":"2016","unstructured":"Gong, H., Li, Y., Wang, L., Lv, Q. & Wang, X. Short-term effects of \u03b22-AR blocker ICI 118,551 on sarcoplasmic reticulum SERCA2a and cardiac function of rats with heart failure. Exp Ther Med. Sep 12(3), 1355\u20131362 (2016).","journal-title":"Exp Ther Med. Sep"},{"issue":"1","key":"46448_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000369075","volume":"95","author":"S Propping","year":"2015","unstructured":"Propping, S., Newe, M., Lorenz, K., Wirth, M. P. & Ravens, U. \u03b2-Adrenoceptor-Mediated Relaxation of Carbachol-Pre-Contracted Mouse Detrusor. Urol Int. 95(1), 92\u201398 (2015).","journal-title":"Urol Int."},{"issue":"1","key":"46448_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-019-0450-7","volume":"12","author":"M Sonekatsu","year":"2019","unstructured":"Sonekatsu, M., Gu, S. L., Kanda, H. & Gu, J. G. Effects of norepinephrine and \u03b22 receptor antagonist ICI 118,551 on whisker hair follicle mechanoreceptors dissatisfy Merkel discs being adrenergic synapses. Mol Brain. 12(1), 31 (2019).","journal-title":"Mol Brain."},{"issue":"5","key":"46448_CR41","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.3892\/or.2015.3874","volume":"33","author":"M Coelho","year":"2015","unstructured":"Coelho, M. et al. Antiproliferative effects of \u03b2-blockers on human colorectal cancer cells. Oncol Rep. 33(5), 2513\u20132520 (2015).","journal-title":"Oncol Rep"},{"issue":"7","key":"46448_CR42","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/cas.13275","volume":"108","author":"H Chen","year":"2017","unstructured":"Chen, H. et al. \u03b22-AR activation induces chemoresistance by modulating p53 acetylation through upregulating Sirt1 in cervical cancer cells. Cancer Sci. 108(7), 1310\u20131317 (2017).","journal-title":"Cancer Sci."},{"issue":"Suppl A","key":"46448_CR43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/eurheartj\/11.suppl_A.54","volume":"11","author":"PM McCaffrey","year":"1990","unstructured":"McCaffrey, P. M., Riddell, J. G. & Shanks, R. G. Selectivity of xamoterol, prenalterol and salbutamol as assessed by their effects in the presence and absence of ICI 118,551. Eur Heart J. Apr 11(Suppl A), 54\u20135 (1990).","journal-title":"Eur Heart J. Apr"},{"key":"46448_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature. 414, 105\u2013111 (2001).","journal-title":"Nature."},{"key":"46448_CR45","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/jcp.25759","volume":"232","author":"MR Abbaszadegan","year":"2017","unstructured":"Abbaszadegan, M. R. et al. Isolation, identification, and characterization of cancer stem cells: A review. J Cell Physiol. 232, 2008\u20132018 (2017).","journal-title":"J Cell Physiol"},{"issue":"12","key":"46448_CR46","doi-asserted-by":"publisher","first-page":"e28385","DOI":"10.1371\/journal.pone.0028385","volume":"6","author":"Irene Abreu-Rodr\u00edguez","year":"2011","unstructured":"Abreu-Rodr\u00edguez, I. et al. Functional and transcriptional induction of aquaporin-1 gene by hypoxia; analysis of promoter and role of Hif-1\u03b1. PLoS One. 6(12) (2011).","journal-title":"PLoS ONE"},{"issue":"3","key":"46448_CR47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s11596-008-0327-y","volume":"28","author":"T Yin","year":"2008","unstructured":"Yin, T. et al. Correlation between the expression of aquaporin 1 and hypoxia-inducible factor 1 in breast cancer tissues. J Huazhong Univ Sci Technolog Med Sci. 28(3), 346\u2013348 (2008).","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"46448_CR48","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1124\/mol.64.6.1357","volume":"64","author":"JG Baker","year":"2003","unstructured":"Baker, J. G., Hall, I. P. & Hill, S. J. Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol. Pharmacol. 64, 1357\u20131369 (2003).","journal-title":"Mol. Pharmacol."},{"key":"46448_CR49","doi-asserted-by":"crossref","unstructured":"Zhang, C. et al. Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget 8 (2017).","DOI":"10.18632\/oncotarget.18125"},{"key":"46448_CR50","unstructured":"Gl\u00e4sker, V. & Klingler, J. H. RareConnect.org webinar: Hemangioblastomas of the central nervous system in patients with VHL, https:\/\/youtu.be\/F0wSl9AQxrg (2018)."},{"key":"46448_CR51","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(18)30533-3","volume":"19","author":"RH Giles","year":"2018","unstructured":"Giles, R. H. & Gl\u00e4sker, S. The first prospective trial for von Hippel-Lindau disease: pazopanib. Lancet Oncol. 19, 1267\u20131269 (2018).","journal-title":"Lancet Oncol."},{"key":"46448_CR52","unstructured":"Shepard, M. J. et al. Repurposing propranolol as an antitumor agent in von Hippel-Lindau disease. J. Neurosurg. 1\u20139 (2018)."},{"key":"46448_CR53","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/carcin\/bgx146","volume":"39","author":"D Rinc\u00f3n-Fern\u00e1ndez","year":"2018","unstructured":"Rinc\u00f3n-Fern\u00e1ndez, D. et al. In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines. Carcinogenesis. 39, 447\u2013457 (2018).","journal-title":"Carcinogenesis."},{"key":"46448_CR54","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s11060-018-2763-2","volume":"137","author":"YC Liu","year":"2018","unstructured":"Liu, Y. C., Lee, I. C. & Chen, P. Y. Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype. J Neurooncol. 137, 511\u2013522 (2018).","journal-title":"J Neurooncol."},{"issue":"6","key":"46448_CR55","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2174\/15665240113139990055","volume":"13","author":"T Shan","year":"2013","unstructured":"Shan, T. et al. \u03b22-AR-HIF-1\u03b1: a novel regulatory axis for stress-induced pancreatic tumor growth and angiogenesis. Curr Mol Med. 13(6), 1023\u20131034 (2013).","journal-title":"Curr Mol Med"},{"issue":"9\u201310","key":"46448_CR56","doi-asserted-by":"crossref","first-page":"264","DOI":"10.18632\/oncoscience.472","volume":"5","author":"DC Galv\u00e1n","year":"2018","unstructured":"Galv\u00e1n, D. C., Ayyappan, A. P. & Bryan, B. A. Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment. Oncoscience. 5(9\u201310), 264\u2013268 (2018).","journal-title":"Oncoscience."},{"key":"46448_CR57","doi-asserted-by":"crossref","unstructured":"De Giorgi, V. et al. Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. JAMA Oncol. 4(2) (2018).","DOI":"10.1001\/jamaoncol.2017.2908"},{"key":"46448_CR58","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.12688\/f1000research.13185.1","volume":"6","author":"MA D\u00edaz-Castellanos","year":"2017","unstructured":"D\u00edaz-Castellanos, M. A. et al. Case Report: Propranolol increases the therapeutic response to temozolomide in a patient with metastatic paraganglioma. F1000Res. 6, 2087 (2017).","journal-title":"F1000Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46448-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46448-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46448-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:20:35Z","timestamp":1671276035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46448-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["46448"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-46448-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,11]]},"assertion":[{"value":"17 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10062"}}